BioInvent Interim Report 1 January – 30 September 2013

Regulatory News:

BioInvent (STO:BINV):

Achieved milestones and extended research collaborations generate SEK 55 million net sales in third quarter and after closing date

Third quarter 2013

· Net sales for January – September 2013 amounted to SEK 32 (34) million, whereof the third quarter SEK 7,8 (13) million.

· Earnings after tax for January – September 2013: SEK -39 (-166) million. Earnings per share before and after dilution SEK -0.51 (-2.33). Earnings after tax for the third quarter was SEK -15 (-37) million.

· Liquid funds as of 30 September 2013: SEK 40 (153) million. Cash flow of current operations and investment activities for January – September 2013: SEK -80 (-118) million, whereof the third quarter SEK -19 (-34) million.

Important events in the third quarter and after the end of the reporting period

· BioInvent announced in October that a significant license fee is received when BioInvent and Bayer extend and broaden collaboration for the development of therapeutic antibodies.

· BioInvent received in July a milestone payment when a partner programme entered the clinical phase.

· Total revenues from the agreement with Bayer and other achieved milestones and extensions of research collaborations announced during the third quarter and after the closing date amounts to SEK 55 million. The greater part of this amount is related to the agreement with Bayer and will be recognized as revenue in the fourth quarter.

· An oversubscribed rights issue worth SEK 23 million before transaction costs was concluded in July.

· Michael Oredsson took up the post as BioInvent’s new CEO in August.

Comments from the CEO "We have intensified our efforts to generate revenue from the technology platform which begins to show results. We will further increase our focus on this effort while building an internationally competitive clinical pipeline in partnership with leading pharmaceutical and biotech companies.", says Michael Oredsson, CEO of BioInvent.

The report is also available at www.bioinvent.com

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR® and the screening tool F.I.R.S.T.TM are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase.

The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe and Servier.

Information disclosed in this interim report is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 24 October, 2013.

This information was brought to you by Cision http://news.cision.com